Abstract:Intravitreal injections of ranibizumab, an anti–vascular endothelial growth factor (VEGF) antibody for the treatment of patients with exudative age-related macular degeneration (AMD) has a remarkably favorable visual outcome compared with previous treatments. Despite its dramatic therapeutic effect, there is concern about possible systemic thromboembolic complications because its anti-angiogenic effect is potentially deleterious to normal cerebrocardiac functions. However, to date no study has had a sample size large enough to determine whether intravitreal ranibizumab injections increase the risk of adverse systemic effects. The authors conducted a systematic review of the literature to investigate the relationship between the intravitreal injection of ranibizumab and systemic arterial thromboembolic events (ATEs). Using PubMed, Cochrane Controlled Trials Register, and ClinicalTrials.gov relevant studies were extracted using the search terms “ranibizumab” and “age-related macular degeneration.” Among the studies that included these keywords, prospective randomized clinical trials (RCTs) were selected and reviewed. The frequencies of ATEs after intravitreal injection of ranibizumab were reported in 4 RCTs.1Antoszyk A. Tuomi L. Chung C. Singh A. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results.Am J Ophthalmol. 2008; 145: 862-874Abstract Full Text Full Text PDF PubMed Scopus (190) Google Scholar, 2Brown D. Kaiser P. Michels M. et al.Ranibizumab versus verteporfin for neovascular age-related macular degeneration.N Engl J Med. 2006; 355: 1432-1444Crossref PubMed Scopus (2931) Google Scholar, 3Regillo C. Brown D. Abraham P. et al.Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.Am J Ophthalmol. 2008; 145: 239-248Abstract Full Text Full Text PDF PubMed Scopus (740) Google Scholar, 4Rosenfeld P. Brown D. Heier J. et al.Ranibizumab for neovascular age-related macular degeneration.N Engl J Med. 2006; 355: 1419-1431Crossref PubMed Scopus (4634) Google Scholar In 3 of the 4 studies, the results of the monthly injections and the occurrence of adverse systemic effects for 2-year observation periods were available.1Antoszyk A. Tuomi L. Chung C. Singh A. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results.Am J Ophthalmol. 2008; 145: 862-874Abstract Full Text Full Text PDF PubMed Scopus (190) Google Scholar, 2Brown D. Kaiser P. Michels M. et al.Ranibizumab versus verteporfin for neovascular age-related macular degeneration.N Engl J Med. 2006; 355: 1432-1444Crossref PubMed Scopus (2931) Google Scholar, 4Rosenfeld P. Brown D. Heier J. et al.Ranibizumab for neovascular age-related macular degeneration.N Engl J Med. 2006; 355: 1419-1431Crossref PubMed Scopus (4634) Google Scholar These were the MARINA (Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular Age-Related Macular Degeneration), ANCHOR (Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration), and FOCUS (RhuFab V2 Ocular Treatment Combining the Use of Visudyne to Evaluate Safety) studies, which had been conducted with manufacturer support. Baseline data on the enrolled subjects was available for each study and was similar across the studies. The MARINA and ANCHOR studies stated that no patient had been excluded because of preexisting cardiovascular, cerebrovascular, or peripheral vascular conditions. The FOCUS study did not refer to this point specifically. In each of the 3 studies the reporting protocol for ATEs was unclear. It is therefore not clear whether the number presented covered all incidences of ATEs or just cases having a speculative relationship with the treatment, as judged by the assigned investigators. The numbers of subjects who had experienced cerebrovascular accidents (CVA) or nonfatal myocardial infarction (MI) were extracted from each study and meta-analysis was performed. The frequencies of CVA and MI between the 2 groups—namely, those who received monthly intravitreal injections of ranibizumab (either 0.5 mg or 0.3 mg per injection), and those who received sham treatment—were compared. Descriptions of strokes, transient ischemic attacks, or cerebral ischemic incidents were regarded as CVA in the present study. One subject in the FOCUS study who had been categorized into coronary artery occlusion was regarded as MI for the purposes of the current study. One subject in MARINA study who had been scheduled to receive sham treatment, but who actually received one injection of ranibizumab by mistake was excluded from the current study. The number of subjects with CVA or MI was dichotomously scored and because of the low event rate, odds ratios (OR) with 95% confidence intervals (CI) were used to estimate the effect. The homogeneity of the odds ratios between the studies was investigated and Mantel-Haenszel odds ratios were calculated. As shown in Table 1 (available at http://aaojournal.org), through the MARINA, ANCHOR, and FOCUS studies, 859 subjects were treated with monthly ranibizumab, and 434 subjects were sham-treated. During the 2-year observation period, 19 of the ranibizumab-treated subjects (2.2%) were found to have CVA, whereas 16 (1.9%) were found to have MI. Of the sham-treated subjects, 3 (0.7%) were found to have experienced CVA, whereas 13 (3.0%) were found with MI during the period. According to the current meta-analysis, intravitreal ranibizumab was associated with the incidence of CVA (P = 0.045; OR, 3.24; 95%CI, 0.96–10.95), whereas there was no apparent association between intravitreal ranibizumab and MI (P = 0.193).Table 1The Numbers of Subjects with Cerebrovascular Accident or Myocardial Infarction across the 3 Randomized Controlled TrialsRanibizumabMARINAANCHORFOCUS+−+−+−Sample Size47723527714310556CVA11 (2.3%)2 (0.9%)2 (0.7%)1 (0.7%)6 (5.7%)0 (0%)OR⁎Mantel-Haenszel type; 3.24 (95%CI; 0.96-10.95, P = 0.045), Breslow-Day test†Test for homogeneity of odds ratios among studies.P = 0.359MI11 (2.3%)6 (2.6%)4 (1.4%)4 (2.8%)1 (1.0%)3 (5.4%)OR 0.61 (0.29-1.29, P = 0.193), P = 0.367CVA + MI21 (4.4%)8 (3.4%)6 (2.2%)5 (3.5%)7 (6.7%)3 (5.4%)OR 1.08 (0.59-1.98, P = 0.888), P = 0.568CVA= cerebrovascular accident; MI = myocardial infarction. Mantel-Haenszel type;† Test for homogeneity of odds ratios among studies. Open table in a new tab CVA= cerebrovascular accident; MI = myocardial infarction. These results indicate an association between intravitreal injections of ranibizumab and the subsequent incidence of CVA. The authors recommend that patients be made aware of this complication before treatment. The dose per injection or the interval between injections, as well as combination therapies such as photodynamic therapy should receive further study as approaches to achieve a balance between safety and efficacy. The central nervous system seems to be adversely affected by even a small amount of ranibizumab injected into the vitreous body. Stroke and Anti-VEGF TherapyOphthalmologyVol. 118Issue 10PreviewIn recent years, anti-vascular endothelial growth factor (anti-VEGF) therapy has been shown to be effective for exudative age-related macular degeneration (AMD). However, the theoretically increased risk of cerebrovascular accidents or stroke that accompanies this therapy is a widely discussed concern.1–4 This report describes an industry-independent, cohort study that evaluated brain magnetic resonance imaging (MRI) scans of patients with exudative AMD who were treated additionally with pan-VEGF isoform antagonists. Full-Text PDF

Cardiovascular and cerebrovascular adverse events associated with intravitreal anti-vascular endothelial growth factor monoclonal antibodies: a World Health Organization pharmacovigilance study

Do Intravitreal Anti-Vascular Endothelial Growth Factor Agents Lead to Renal Adverse Events? A Pharmacovigilance Real-World Study

A real-world data analysis of ocular adverse events linked to anti-VEGF drugs: a WHO-VigiAccess study

Systemic Arterial and Venous Thrombotic Events Associated With Anti–Vascular Endothelial Growth Factor Injections: A Meta-Analysis

A Meta-Analysis of Cardiovascular Events Associated with Intravitreal Anti-VEGF Treatment in Patients with Retinal Vein Occlusion

Cerebrovascular Accidents in Ranibizumab

Similar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and Bevacizumab: An Observational Health Data Sciences and Informatics Network Study

Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.

Systemic Adverse Events After Intravitreal Bevacizumab Versus Ranibizumab For Age-Related Macular Degeneration: A Meta-Analysis

Systemic Vascular Safety of Ranibizumab for Age-Related Macular Degeneration: Systematic Review and Meta-analysis of Randomized Trials

Different Anti-Vascular Endothelial Growth Factor for Patients With Diabetic Macular Edema: A Network Meta-Analysis

Five Years of Safety Profile of Bevacizumab: an Analysis of Real-World Pharmacovigilance and Randomized Clinical Trials

Risk of renal damage associated with intravitreal anti-VEGF therapy for diabetic macular edema in routine clinical practice

Submacular Hemorrhage Rates Following Anti-Vascular Endothelial Growth Factor Injections for Exudative Age-Related Macular Degeneration

Comparative efficacy of anti-vascular endothelial growth factor on diabetic macular edema diagnosed with different patterns of optical coherence tomography: A network meta-analysis

Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion

Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture

Retrospective analysis of the etiology and drugs for vitreous hemorrhage caused by non-diabetic retinopathy and non-traumatic factors

Comparison of the Efficacy and Safety of Drug Therapies for Macular Edema Secondary to Central Retinal Vein Occlusion.

Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines

Comparative efficacy and safety of anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: systematic review and Bayesian network meta-analysis